← Back to Screener
Korro Bio, Inc. Common Stock (KRRO)
Price$10.72
Value ScoreC
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)80.14%
Price vs S&P 500 (4W)-11.03%
VGM Score37.72
Market Capitalization$154.61M
All Metrics
Book Value / Share (Quarterly)$8.29
P/TBV (Annual)4.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-23.12%
Cash Flow / Share (Quarterly)$-4.90
Price vs S&P 500 (YTD)25.67%
Net Profit Margin (TTM)-1834.48%
EPS (TTM)$-11.67
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-11.67
Revenue Growth (5Y)-26.07%
EPS (Annual)$-12.48
ROI (Annual)-227.96%
Gross Margin (Annual)44.73%
Net Profit Margin (5Y Avg)-1161.48%
Cash / Share (Quarterly)$7.90
Revenue Growth QoQ (YoY)-43.11%
ROA (Last FY)-103.31%
Revenue Growth TTM (YoY)-20.31%
EBITD / Share (TTM)$-11.44
ROE (5Y Avg)-87.08%
Operating Margin (TTM)-1906.37%
Cash Flow / Share (Annual)$-8.40
P/B Ratio1.29x
P/B Ratio (Quarterly)1.36x
Net Income / Employee (Annual)$-2,021,700
EV / Revenue (TTM)14.54x
Net Interest Coverage (TTM)-57.71x
ROA (TTM)-71.04%
EPS Incl Extra (Annual)$-12.48
Current Ratio (Annual)6.90x
Quick Ratio (Quarterly)7.71x
3-Month Avg Trading Volume0.19M
52-Week Price Return-13.20%
Revenue / Employee (TTM)$66,200
Tangible BV / Share (Quarterly)$49.74
P/S Ratio (Annual)24.19x
Asset Turnover (Annual)0.06x
52-Week High$55.89
Operating Margin (5Y Avg)-1270.34%
EPS Excl Extra (Annual)$-12.48
CapEx CAGR (5Y)-40.02%
Tangible BV CAGR (5Y)32.33%
26-Week Price Return88.07%
Quick Ratio (Annual)6.38x
13-Week Price Return-2.10%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.13x
Enterprise Value$92.91M
Revenue / Share Growth (5Y)-6.05%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)29.09%
Revenue / Employee (Annual)$110,200
Pretax Margin (Annual)-1824.52%
Cash / Share (Annual)$7.98
3-Month Return Std Dev90.04%
Net Income / Employee (TTM)$-1,956,900
ROE (Last FY)-227.96%
Net Interest Coverage (Annual)-36.96x
EPS Basic Excl Extra (Annual)$-12.48
Receivables Turnover (TTM)3.99x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-11.67
Receivables Turnover (Annual)4.80x
ROI (TTM)-117.86%
P/S Ratio (TTM)24.19x
Pretax Margin (5Y Avg)-1158.23%
Revenue / Share (Annual)$0.68
Tangible BV / Share (Annual)$98.12
Price vs S&P 500 (52W)-37.56%
Year-to-Date Return33.83%
5-Day Price Return-17.09%
EPS Normalized (Annual)$-12.48
ROA (5Y Avg)-54.56%
Net Profit Margin (Annual)-1834.48%
Month-to-Date Return-20.06%
Cash Flow / Share (TTM)$-79.22
EBITD / Share (Annual)$-12.51
Operating Margin (Annual)-1906.37%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-87.08%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-11.67
P/TBV (Quarterly)8.34x
P/B Ratio (Annual)1.47x
Pretax Margin (TTM)-1824.52%
Book Value / Share (Annual)$5.46
Price vs S&P 500 (13W)-10.36%
Beta3.05x
P/FCF (Annual)4.66x
Revenue / Share (TTM)$0.33
ROE (TTM)-117.86%
52-Week Low$5.20
vGradeC
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-1.69est. -1.88
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.06
4.06
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KRROKorro Bio, Inc. Common Stock | C | F | C | $10.72 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Korro Bio is a biopharmaceutical company developing RNA-editing genetic medicines to treat rare and prevalent diseases. The company's proprietary platform leverages the body's natural RNA editing process to create precise, transient single-base edits with greater reversibility than traditional DNA-editing approaches. This differentiated technology positions Korro Bio to address significant unmet medical needs in genetic medicine with enhanced precision and tunability.